The eight main blood types are A+, A-, B+, B-, O+, O-, AB+, and AB-. The most common blood type in the United States is O-positive, with around 38 percent of the population having this type of blood. However, blood type O-positive is more common in Latino-Americans than other ethnicities, with around 53 percent of Latino-Americans with this blood type, compared to 47 percent of African Americans and 37 percent of Caucasians. Blood donation The American Red Cross estimates that every two seconds someone in the United States needs blood or platelets, highlighting the importance of blood donation. It was estimated that in 2021, around 6.5 million people in the U.S. donated blood, with around 1.7 million of these people donating for the first time. Those with blood type O-negative are universal blood donors, meaning their blood can be transfused for any blood type. Therefore, this blood type is the most requested by hospitals. However, only about seven percent of the U.S. population has this blood type. Blood transfusion Blood transfusion is a routine procedure that involves adding donated blood to a patient’s body. There are many reasons why a patient may need a blood transfusion, including surgery, cancer treatment, severe injury, or chronic illness. In 2021, there were around 10.76 million blood transfusions in the United States. Most blood transfusions in the United States occur in an inpatient medicine setting, while critical care accounts for the second highest number of transfusions.

The most common blood type among the population in the United States is O-positive. Around 53 percent of the Latino-American population in the U.S. has blood type O-positive, while only around 37 percent of the Caucasian population has this blood type. The second most common blood type in the United States is A-positive. Around 33 percent of the Caucasian population in the United States has A-positive blood type. Blood type O-negative Those with blood type O-negative are universal donors as this type of blood can be used in transfusions for any blood type. O-negative blood type is most common in the U.S. among Caucasian adults. Around eight percent of the Caucasian population has type O-negative blood, while only around one percent of the Asian population has this blood type. Only around seven percent of all adults in the United States have O-negative blood type. Blood Donations The American Red Cross estimates that someone in the United States needs blood every two seconds. However, only around three percent of age-eligible people donate blood yearly. The percentage of adults who donated blood in the United States has not fluctuated much for the past two decades. In 2021, around 15 percent of U.S. adults donated blood, the same share reported in the year 2003.

This statistic illustrates the distribution of blood groups in the French population, according to the ABO system. It states that less than 5 percent of French people have the AB blood group.

More than twelve blood group systems have been described in dogs, but little is known about their distribution frequencies within breed populations. Here, we report on an extensive typing survey carried out using available reagents and either established or new clinical kits in purebred dogs from Germany. Leftover anticoagulated blood samples were examined using an immunochromatographic strip method for DEA 1, a gel column technique for Dal and Kai 1/2, and new card agglutination tests for DEA 4 and DEA 5 (which were partially compared with the gel column technique). Monoclonal antibodies were used for DEA 1 and Kai 1/2 typing, and polyclonal antibodies were used for all other types. Among the 206 dogs, 59.2% were DEA 1+, 100% DEA 4+, 9% (Card)/11% (Gel) DEA 5+, 89.3% Dal+, 96.6% Kai 1+, and 2.9% Kai 2+. None of the dogs were Kai 1+/2+, and only one was Kai 1–/2–. Dal– dogs were found in several breeds. Erythrocytes from most DEA 1+ dogs bound strongly on the strips. The agglutination reactions for DEA 5 on the new card tests were generally less than those on the gel column. The blood group pattern DEA 4+, DEA 5–, Dal+, Kai 1+/2– and either DEA 1+ or DEA 1– was found among 80% of the dogs. In this first extensive blood typing survey of purebred dogs from Europe, the proportions of positive and negative blood types were similar to those found in the United States and, for DEA 1, were also similar to those from other European countries, with considerable breed variation in blood types. The newer typing techniques seem to work well and will likely be useful for detecting and preventing specific blood type incompatibilities in the clinic.

Statistics illustrates market overview of blood-grouping reagents in the United States from 2007 to 2024.

This industry includes facilities that primarily collect (through donation), test, process and store blood for later use. The testing includes compatibility testing for transfusion and may include blood donation processing. The industry does not include facilities that primarily provide diagnostic tests.

Statistics illustrates the net export volume of Blood-Grouping Reagents in China from 2007 to 2024 by trade partner.

Statistics illustrates the export value of Blood-Grouping Reagents in Hong Kong SAR from 2007 to 2024 by trade partner.

Statistics illustrates the export volume of Blood-Grouping Reagents in Hong Kong SAR from 2007 to 2024 by trade partner.

Global Blood Bank Management Software Market was valued at USD 1.2 Billion in 2024 and is projected to reach USD 2.4 Billion by 2032, growing at a CAGR of 9.0% from 2025 to 2032.Key Market Drivers: Increasing Demand for Blood Transfusions and Donations: The blood bank management software market is being driven by an increase in surgical procedures, trauma cases, and chronic disease therapy that require blood transfusions. According to the World Health Organization (WHO), around 118.5 million blood donations are collected worldwide each year, with demand increasing by 6-8% annually. According to the American Red Cross, someone in the United States needs blood every two seconds, resulting in a daily requirement of around 29,000 units of red blood cells, underlining the crucial need for effective blood inventory systems.Technological Developments in Healthcare Informatics: The adoption of sophisticated technologies such as cloud computing, artificial intelligence, and blockchain in blood bank operations is driving market expansion. According to the US Department of Health and Human Services' Office of the National Coordinator for Health Information Technology, 94% of hospitals will have implemented at least basic electronic health record systems by 2023, with blood bank management becoming an increasingly important component. The European Commission's Digital Health Initiative discovered that healthcare facilities that used integrated blood bank software systems reduced transfusion-related mistakes by 61% between 2020 and 2023.

Statistics illustrates the net export value of Blood-Grouping Reagents in Iceland from 2007 to 2024 by trade partner.

United States Imports: cif: Blood-Grouping Reagents data was reported at 3.860 USD mn in Dec 2021. This records a decrease from the previous number of 4.762 USD mn for Nov 2021. United States Imports: cif: Blood-Grouping Reagents data is updated monthly, averaging 1.862 USD mn from Jan 2002 (Median) to Dec 2021, with 240 observations. The data reached an all-time high of 8.397 USD mn in Jun 2017 and a record low of 0.077 USD mn in Feb 2006. United States Imports: cif: Blood-Grouping Reagents data remains active status in CEIC and is reported by U.S. Census Bureau. The data is categorized under Global Database’s United States – Table US.JA132: Imports: by Commodity: 6 Digit HS Code: HS 30 to 48.

The global blood bank market, valued at $32.03 billion in 2025, is projected to experience robust growth, driven by a rising global population, increasing prevalence of chronic diseases requiring blood transfusions (e.g., cancer, thalassemia), and advancements in blood storage and processing technologies. The increasing demand for safe and readily available blood products, particularly in developing nations, is a significant growth catalyst. Furthermore, growing awareness regarding blood donation and government initiatives promoting blood donation campaigns are contributing to market expansion. Technological advancements such as automated blood component separation systems and improved blood screening techniques enhance efficiency and safety, further fueling market growth. However, challenges remain, including the limited availability of volunteer donors in certain regions, stringent regulatory frameworks governing blood collection and processing, and the potential risk of blood-borne diseases. Segmentation reveals that hospitals are the largest consumers of blood products, followed by laboratories and blood centers. Whole blood currently holds the largest market share among blood product types, though the demand for specialized components like platelets and plasma is growing rapidly due to their critical roles in various medical treatments. The market's geographic distribution reflects varying healthcare infrastructure and donation rates across regions. North America, particularly the United States, dominates the market due to advanced healthcare facilities and high per capita blood donation rates. Europe follows as a significant market, while Asia-Pacific is expected to witness rapid growth in the coming years driven by rising disposable income and increasing healthcare expenditure. Competition among key players, including both large national blood banks and smaller regional players, is intense, marked by investments in R&D, strategic partnerships, and expansion into new markets. The forecast period (2025-2033) anticipates a sustained CAGR of 6.5%, reflecting the continued demand for blood products and ongoing efforts to improve blood bank infrastructure and processes globally. This growth will likely be influenced by factors such as technological innovations, expanding healthcare infrastructure, and evolving public health initiatives.

United States Exports: Blood-Grouping Reagents data was reported at 6.693 USD mn in Dec 2021. This records an increase from the previous number of 6.040 USD mn for Nov 2021. United States Exports: Blood-Grouping Reagents data is updated monthly, averaging 8.577 USD mn from Jan 2002 (Median) to Dec 2021, with 240 observations. The data reached an all-time high of 19.292 USD mn in Mar 2002 and a record low of 1.754 USD mn in Dec 2003. United States Exports: Blood-Grouping Reagents data remains active status in CEIC and is reported by U.S. Census Bureau. The data is categorized under Global Database’s United States – Table US.JA023: Exports: by Commodity: 6 Digit HS Code: HS 21 to 35.

In 2021, there were an estimated 274 blood transfusion-associated adverse reactions in the United States that required any diagnostic or therapeutic intervention per 100,000 components transfused. This graph shows the estimated rate of blood transfusion-associated adverse reactions in the United States in 2019 and 2021, by type, per 100,000 components transfused.

Statistics illustrates the export value of Blood-Grouping Reagents in Brunei Darussalam from 2007 to 2024 by trade partner.

In 2023, there were ****** people in the United States who had hemophilia A and around ***** people were diagnosed with hemophilia B. This statistic displays the number of people in the U.S. diagnosed with a blood disorder by disorder type, as of 2023.

The global market size of Synthetic Type Colloids (Blood Plasma) is $XX million in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million by the end of 2024 with a CAGR of XX% from 2019 to 2024.
Global Synthetic Type Colloids (Blood Plasma) Market Report 2019 - Market Size, Share, Price, Trend and Forecast is a professional and in-depth study on the current state of the global Synthetic Type Colloids (Blood Plasma) industry. The key insights of the report:
1.The report provides key statistics on the market status of the Synthetic Type Colloids (Blood Plasma) manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.
2.The report provides a basic overview of the industry including its definition, applications and manufacturing technology.
3.The report presents the company profile, product specifications, capacity, production value, and 2013-2018 market shares for key vendors.
4.The total market is further divided by company, by country, and by application/type for the competitive landscape analysis.
5.The report estimates 2019-2024 market development trends of Synthetic Type Colloids (Blood Plasma) industry.
6.Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out
7.The report makes some important proposals for a new project of Synthetic Type Colloids (Blood Plasma) Industry before evaluating its feasibility.
There are 4 key segments covered in this report: competitor segment, product type segment, end use/application segment and geography segment.
For competitor segment, the report includes global key players of Synthetic Type Colloids (Blood Plasma) as well as some small players.
The information for each competitor includes:
* Company Profile
* Main Business Information
* SWOT Analysis
* Sales, Revenue, Price and Gross Margin
* Market Share

For product type segment, this report listed main product type of Synthetic Type Colloids (Blood Plasma) market
* Product Type I
* Product Type II
* Product Type III

For end use/application segment, this report focuses on the status and outlook for key applications. End users sre also listed.
* Application I
* Application II
* Application III

For geography segment, regional supply, application-wise and type-wise demand, major players, price is presented from 2013 to 2023. This report covers following regions:
* North America
* South America
* Asia & Pacific
* Europe
* MEA (Middle East and Africa)
The key countries in each region are taken into consideration as well, such as United States, China, Japan, India, Korea, ASEAN, Germany, France, UK, Italy, Spain, CIS, and Brazil etc.

Reasons to Purchase this Report:
* Analyzing the outlook of the market with the recent trends and SWOT analysis
* Market dynamics scenario, along with growth opportunities of the market in the years to come
* Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and non-economic aspects
* Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
* Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
* Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
* Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
* 1-year analyst support, along with the data support in excel format.
We also can offer customized report to fulfill special requirements of our clients. Regional and Countries report can be provided as well.

Statistics illustrates the import volume of Reagents; diagnostic or laboratory reagents on a backing, prepared diagnostic or laboratory reagents whether or not on a backing, whether or not put up in the form of kits; for blood grouping in Guatemala from 2007 to 2024 by trade partner.

The global blood preparation market, valued at approximately $XX million in 2025, is projected to experience robust growth, exhibiting a Compound Annual Growth Rate (CAGR) of 5.50% from 2025 to 2033. This expansion is driven by several key factors. The rising prevalence of chronic diseases like cardiovascular disorders and hematological malignancies necessitates increased demand for blood components and derivatives. Technological advancements in blood processing and storage, leading to improved safety and efficacy, are further fueling market growth. Moreover, increasing geriatric populations in developed nations contribute significantly to the demand, as older individuals are more susceptible to conditions requiring blood transfusions and related treatments. The segment dominated by blood components, owing to their widespread use in various medical procedures. Within blood-thinning agents, anticoagulants hold a significant market share due to their crucial role in preventing blood clots in high-risk patients. Geographically, North America and Europe currently hold the largest market share, driven by advanced healthcare infrastructure and high healthcare expenditure. However, Asia-Pacific is poised for significant growth in the coming years due to rapid economic development and rising healthcare awareness. Regulatory approvals for innovative blood preparation technologies and expanding healthcare infrastructure in emerging economies will further stimulate market growth. Despite the positive outlook, certain challenges hinder market expansion. The high cost associated with blood preparation and storage infrastructure remains a significant barrier, particularly in developing countries. Stringent regulatory requirements for product safety and efficacy can also delay market entry for new products. Furthermore, the dependence on voluntary blood donations presents an ongoing challenge to ensure consistent supply, especially during periods of high demand. Addressing these challenges through public awareness campaigns, investment in advanced technologies, and streamlining regulatory processes will be crucial for sustained growth in the blood preparation market. Competitive landscape is intense with major pharmaceutical and biotech companies vying for market share through innovation and strategic acquisitions. Recent developments include: November 2022- ImmunoTek Plasma opened a new plasma collection center in Indianapolis. They have plasma collection centers in 12 states and another Indiana location in Jeffersonville, United States., February 2022- Bayer AG won fast-track status from United States drug regulators for a new blood thinner designed to prevent certain types of strokes as it seeks to follow up on the success of its anticoagulant, Xarelto.. Key drivers for this market are: Growing Demand of Blood and Its Components in Surgeries, Growing Initiatives by Government and Private Sector; Increasing Geriatric Population. Potential restraints include: Growing Demand of Blood and Its Components in Surgeries, Growing Initiatives by Government and Private Sector; Increasing Geriatric Population. Notable trends are: Whole Blood is Expected to Have a Significant Growth Over the Forecast Period.